AlgemeneGezondheid.Org

NewCardio to unveil patented CardioBip technology at HRS Annual Scientific Sessions

November 15, 2017

In addition, and as previously announced, the HRS has accepted an abstract  detailing the superior performance of NewCardio's CardioBip, particularly in patients with atrial fibrillation for its oral presentation.  The abstract, titled "Three-dimensional Atrial Signal Reconstruction Facilitates Remote Detection Of Atrial Fibrillation," was Alexei Shvilkin, MD, PhD, Dejan Vukajlovic, MD, Vladan Vukcevic, MD, Ihor Gussak, MD, PhD, Bosko Bojovic, PhD, Uros Mitrovic, MS and Goran Simic, MS.  The abstract discusses the use of CardioBip for improved atrial fibrillation (AF) monitoring and detection, highlighting a new AF detection algorithm based on NewCardio's proprietary 3-D ECG processing platform.

The CardioBip is a unique, hand-held device that provides a solution for ECG remote monitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop.  What makes CardioBip unique is its extreme ease of use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs.  The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device's electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms.  The device is not currently approved for sale or distribution in the United States.  On January 12, 2010, the U.S. Patent and Trademark Office issued patent 7,647,093, titled "Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing."  This represents the core patent for CardioBip.  Additional patent applications covering the CardioBip have been submitted.

SOURCE NewCardio, Inc.